Zhen Huang

Director/Board Member at WALVAX BIOTECHNOLOGY CO., LTD.

Net worth: 66 M $ as of 2024-03-30

61 year

Health Technology

Profile

Zhen Huang currently works at Walvax Biotechnology Co., Ltd., as Vice Chairman from 2019, Shanghai Zerun Biotechnology Co., Ltd., as Director, and Yuxi Walvax Biotechnology Co., Ltd., as President.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
WALVAX BIOTECHNOLOGY CO., LTD. CLASS A 1.14%	2023-06-29	17,698,729 ( 1.14% )	38 M $	2024-03-30
WALVAX BIOTECHNOLOGY CO., LTD. 28.09%	2023-09-29	13,274,047 ( 28.09% )	28 M $	2024-03-30

Zhen Huang active positions

Companies	Position	Start
WALVAX BIOTECHNOLOGY CO., LTD.	Director/Board Member	2019-08-21
Yuxi Walvax Biotechnology Co., Ltd.	President	-
Shanghai Zerun Biotechnology Co., Ltd. Shanghai Zerun Biotechnology Co., Ltd. BiotechnologyHealth Technology Shanghai Zerun Biotechnology Co., Ltd. engages in the development, commercialization, and industrialization of new recombinant human vaccine products. It develops recombinant vaccines such as preventive cervical cancer vaccines, and recombinant enterovirus 71 virus-like particle and therapeutic vaccines. The company was founded on May 7, 2003 and is headquartered in Shanghai, China.	Director/Board Member	-

All active positions of Zhen Huang

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Zhen Huang's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
WALVAX BIOTECHNOLOGY CO., LTD.	Health Technology

Private companies	2
Yuxi Walvax Biotechnology Co., Ltd.
Shanghai Zerun Biotechnology Co., Ltd. Shanghai Zerun Biotechnology Co., Ltd. BiotechnologyHealth Technology Shanghai Zerun Biotechnology Co., Ltd. engages in the development, commercialization, and industrialization of new recombinant human vaccine products. It develops recombinant vaccines such as preventive cervical cancer vaccines, and recombinant enterovirus 71 virus-like particle and therapeutic vaccines. The company was founded on May 7, 2003 and is headquartered in Shanghai, China.	Health Technology